New Curcumin Extract Found to Counteract Inflammation At the Transcriptional Level
Vancouver, CANADA, October 5, 2016 – New biomedical research discovery released today shows that a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), is proven to be up to 7X more potent on a key anti-inflammatory target than the curcumin extract itself. This discovery allows curcumin pharmacology to be more precisely targeted for therapeutic results.
The research on this patent-pending discovery is the work of The Rhema Group’s Chief Science Officer, Franco Cavaleri, BSc, PhDc. He is the principal research scientist at Biologic Pharmamedical, and also completing a doctoral degree in Experimental Medicine at UBC’s Faculty of Medicine, Center for Brain Health. Cavaleri’s research shows for the first time how the modified curcumin extract targets and neutralizes a key protein central in the regulation of inflammation while significantly enhancing the efficacy of the anti-inflammatory properties of curcumin.
“Inflammation is central to every disease pathology at one level or another. This new pointed pharmacological research on curcumin reveals that although BDMC exists in extremely low concentrations in standardized curcumin extracts – between 0.5% to 1.5% – it can play a key role in therapy if it is raised to 30%. This enhancement fortifies the mechanism by which curcumin can inhibit nuclear, MSK1, a facilitative kinase protein central to the inflammatory process. MSK1, is more recently shown to be dysregulated in diseases like drug resistant cancers and chronic or drug resistant autoimmune disease.” says Cavaleri.
This new understanding reveals how curcumin pharmacology can be designed to be more selective in targeting specific genomic activity. Elevated levels of BDMC to 30% is showing dramatic results.
The Rhema Group, a leading nutraceutical formulator and manufacturer to global markets, has partnered with Biologic Pharmamedical Research, a private biomedical research organization, to bring to market patent-protected formulations with BDMC levels elevated to 30% under the trade name Curcumin BDM30™. Both companies are working together to use Cavaleri’s patent-pending research to develop new evidence-based curcumin-drug and supplement designs for the functional food and nutraceutical industry. This inflection is expected to change how curcumin is prescribed in the future to help improve lives.